Related Experiment Video
Updated: Oct 17, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection
Deanna Buehrle1, Cornelius J Clancy1,2
1VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Abstract:
We analyzed June 2021 Medicare Advantage/Part D enrollment and formulary data. Oral vancomycin and fidaxomicin, frontline Clostridioides difficile treatments, were in the formulary for 100% (42314676 of 42314676) and 84.1% (35598385 of 42314676) of enrollees, respectively. However, they were broadly accessible (formulary, unrestricted, tier 1 or 2) to only 14.4% (6104348 of 42314676) and 1.1% (483004 of 42314676), respectively.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD

